iCFO CAPITAL · ECOSYSTEM SHOWCASE
Live Web Event for Investors and Founders
iCapOS provides technology and diligence infrastructure for review purposes only. Nothing on this platform is investment advice, a recommendation, or a guarantee of funding, investor participation, allocations, returns, or liquidity. Private offerings are risky and may result in loss of capital. Investors must conduct independent due diligence and issuers should obtain appropriate legal review.
Auditorium: Experience our prequalified deal flows, learn from dynamic presentations, and engage with experts through interactive Q&A sessions.
Inside the Investor’s Mind – Investor Challenge Series is a monthly, investor-grade talk show designed to reveal how CEOs think, decide, and lead under real-world pressure. Each episode features a candid conversation with a CEO, followed by a live investor panel that asks the kinds of questions typically reserved for private diligence discussions. The panel addresses real-world challenges head-on, bringing the unfiltered reality of the investor perspective into the open.
NutriFlex AI solves fragmented health data and generic wellness programs that fail to turn biometric signals into timely, personalized action. Our AI-powered platform transforms wearable data—including sleep, stress, activity, and recovery signals—into adaptive, real-time recommendations that help individuals and organizations improve health, performance, and well-being.
Impervitex solves the massive thermal, environmental, and electronic vulnerabilities in conventional textiles without requiring expensive custom manufacturing or fabric re-engineering. We provide an asset-light Deep Tech Chemistry Platform that programs multi-spectral IR masking, thermal insulation, and EMP shielding directly into existing fabrics using proprietary chemical building blocks. Operating on a high-margin license-per-yard yield model, we enable commercial and defense partners to deploy advanced textile intelligence at scale with zero client-side inventory risk.
Presenter
Steve is a tech visionary, former CEO, and the strategic force driving LivIQ’s advanced "Compliance by Design" infrastructure. Collaborating closely with his co-founder Christopher, he bridges the gap between cutting-edge Web3/DLT principles and scalable, decentralized population health platforms. For today’s iCFO session, Steve is showcasing how LivIQ’s automated data pipelines and bi-coastal logistics are redefining the future of precision medicine.
Company
LivIQ is a tech-first clinical infrastructure firm redefining decentralized diagnostics through an automated, "Compliance by Design" data pipeline. By combining painless collection hardware with a hybrid Web2.5 architecture, the company securely separates patient identity from clinical data to deliver audit-ready, FDA/RWE-grade metrics today, while positioning advanced data intelligence and Web3 decentralization on the immediate product roadmap. Supported by a dual-hub fulfillment model in Phoenix and Greenville, SC, alongside high-impact onsite activation teams, LivIQ enables partners to deploy any diagnostic, anywhere, with total data integrity and zero friction.
Presenter
Shan is a serial entrepreneur who has founded, scaled, and sold three healthcare companies prior to Harvard MedTech. Two of them were medical device companies that had a successful IPO on Nasdaq prior to eventually being sold to a strategic acquirer.
Company
Harvard MedTech's biopsychosocial program is grounded in Behavioral Science and delivered via an in-home Virtual Reality device. The program helps patients who suffer from chronic pain, anxiety, depression, PTSD, and other symptoms of trauma.
Presenter
Tyler is the CEO of Revolution5 Global, an agricultural technology company developing advanced crop input solutions through its proprietary QuantumMatrix™ platform. With over a decade of global agriculture experience, he has led the company’s expansion across multiple international markets, driving innovation in nutrient efficiency and sustainable farming. Tyler is recognized for scaling high-growth platforms by bridging advanced technology with real-world agricultural applications.
Company
Revolution5 Global is building a next-generation agricultural inputs platform designed to solve one of the largest inefficiencies in global farming—where over 60% of fertilizer inputs are lost. Through its proprietary QuantumMatrix™ technology, Rev5 enables farmers to significantly reduce input costs while improving yields, creating immediate economic and environmental value. The Company is moving from validation to commercialization, with a scalable, asset-light model positioned for rapid global expansion. Rev5 is targeting a transformational shift in a $200B+ market undergoing structural change toward efficiency and sustainability.
Presenter
Before developing Brainiest, Alan led a series of landmark industry ‘firsts’ as a senior product marketing and strategic planning executive at Intel, and later as CEO and Director of Strategic Planning for DevelopOnline. His journey with Brainiest is the latest—and perhaps the most rewarding—chapter in a storied career highlighted by technological breakthroughs that changed the game for organizations and people around the world.
Company
Brainiest is an all-in-one AI Marketing Platform targeting SMBs, acting as their 24/7 marketing consultant. The Brainiest Way of accurate and targeted AI Marketing has been validated by Carnegie Mellon’s Tepper School of Business, Rensselaer Polytechnic Institute, and thousands of users. Brainiest's first market fit is coming from local Real Estate associations, realtors, and Regional Banks.
Presenter
Dr. Lode Debrabandere, co-founder and CEO of Amynas, Inc., is a serial entrepreneur who directed IPO’s for two companies and executed over $1.3 billion in M&A transactions.
Company
Amynas, Inc. is a Delaware-based medical technology company with a patent-protected platform engineered to fundamentally improve the body's interaction with implanted medical devices. Our technology is rooted in two pillars: a pro-regenerative nano-biomaterial foundation combined with an anti-infective drug-eluting capability.
Presenter
Bob is a seasoned technology executive currently serving as President & CEO of Scriptive LLC. With over 20 years of leadership experience, he has held significant positions at JD Power, Lands' End, Resonate, Merkle, and Cox Communications. He holds a PhD in Psychology from Wichita State and an executive MBA from the Marriott School of Management.
Company
Scriptive is an EdTech SaaS platform focused on improving writing proficiency in children through imaginative, picture-driven story creation. Their product, WriteStories, allows children to create original stories inspired by illustrations in a curated library of books.
Presenter
Shailesh is a seasoned business leader and entrepreneur with over 36 years of global experience spanning pharmaceutical manufacturing, international trade, human resource management, IT consulting, and hospitality.
Company
SOHM is a globally recognized biotechnology company developing, manufacturing, and distributing an extensive range of high-quality pharmaceutical, cosmeceutical, and nutraceutical products, all backed by its patented genome editing technology. With strong research capabilities at their core and support from trusted manufacturing partners, they’re steadfast in ensuring the highest safety and compliance standards, strictly following guidelines like WHO-CGMP and USFDA.
Presenter
Dr. Jamie is a former Global Architect at the NYSE and Head of Technology for TP ICAP, an expert in EU and US Regs and Market Microstructure.
Company
Clearpool Digital (cplx.oi) brings gravitational tokenomics along with real-world assets and democratized liquidity provision to DeFi derivative markets, removing fragmentation and driving market adoption and growth. They have production-proven tech that targets the key growth opportunity and addresses the pain points holding back the market.
Presenter
Founder and CEO of HoloMD, an award-winning psychiatrist who founded Potomac Psychiatry and developed the precision psychiatry methods behind HoloMD.
Company
HoloMD is a revenue-generating behavioral-health technology company addressing one of psychiatry’s most persistent failures: patients live every day, while clinicians often see only episodic snapshots. Dr. Holo combines doctor-branded daily engagement, artificial intelligence, Human-in-the-Loop (HITL) review, and provider action to identify relapse, deterioration, medication problems, disengagement, and safety concerns earlier - without replacing the treating clinician. The company has built substantial operating proof in approximately 24 months.
Presenter
John is a global supply chain executive with deep expertise in execution and simplification across chemical, life sciences, manufacturing, logistics, and other regulated industries. He is recognized for driving innovation and thought leadership in manufacturing and distribution, bringing operational discipline and strategic clarity to complex, highstakes environments.
Company
Doyle Organics is a trailblazer in sustainable agriculture, offering a line of OMRI-listed, completely synthetic, chemical-free fertilizers and pesticides purpose-built for today's environmentally conscious grower. Founded in Maryland in 2019, the company has achieved nearly $800,000 in cumulative revenue while developing tailored solutions — from slow-release fertilizers to custom crop blends — that prioritize both soil health and food quality. With a motto of "Sustainable Growth Starts Here," Doyle Organics is strategically positioned to capture a significant share of a global organic farming market projected to reach $542 billion by 2033.
Presenter
Dr. Paul is a Founding Partner and Chief Executive Officer of NovaRhythm Biosciences, a biotechnology company focused on developing transformative therapies for cardiac arrhythmias. He brings more than 40 years of experience spanning cardiovascular research, translational medicine, drug development, and biotechnology company leadership. Previously, he co-founded AnaBios Corporation, where he helped build a leading human tissue translational research platform serving major pharmaceutical and biotechnology companies worldwide.
Company
NovaRhythm Biosciences, Inc. is a cardiovascular biotechnology company developing SAR-297871, a highly selective TASK-1 inhibitor for the treatment of atrial fibrillation. The company holds an exclusive worldwide license from Sanofi for the program, which is supported by decades of research, extensive preclinical and human translational data, and approximately $200 million of prior investment. NovaRhythm's strategy is to complete IND-enabling studies and a Phase 1 clinical trial, creating a Phase 2-ready asset positioned for partnership or acquisition by a major pharmaceutical company. The company is focused on addressing a significant unmet medical need while creating substantial value for patients and investors.